Literature DB >> 31057731

Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.

Liam Berry1, Ronald Domalaon1, Marc Brizuela1, George G Zhanel2, Frank Schweizer1,2.   

Abstract

To address the rising threat of multidrug-resistant (MDR) bacteria, new therapeutic strategies must be developed. Efficacious drug combinations consisting of existing antibiotics and enhancer biomolecules called adjuvants offers a viable strategy. We have previously reported antibiotic hybrids consisting of tobramycin appended to different fluoroquinolones that possess potential as stand-alone antimicrobials as well as adjuvants. Herein, we report the synthesis of polybasic peptide-levofloxacin conjugates based on these tobramycin-fluoroquinolone hybrids. It was found that conjugating polybasic peptides to the fluoroquinolone levofloxacin, along with the addition of an aliphatic hydrocarbon tether, resulted in the ability of these compounds to potentiate fluoroquinolones and other antibiotics against MDR Gram-negative bacteria. The conjugates were able to potentiate ciprofloxacin, levofloxacin and moxifloxacin against MDR clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and to a lesser extent, Acinetobacter baumannii. Preliminary data revealed that the conjugates interfered with active efflux of fluoroquinolones in P. aeruginosa. In addition, synergy was observed with a wide array of other antibiotics against P. aeruginosa, including those that suffered from restricted outer membrane penetration, suggesting that in addition to blocking active efflux, the polybasic peptide-levofloxacin conjugates possessed the ability to disrupt and permeabilize the outer membrane of Gram-negative bacteria.

Entities:  

Year:  2019        PMID: 31057731      PMCID: PMC6482413          DOI: 10.1039/c9md00051h

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  27 in total

1.  Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa.

Authors:  L Zhang; P Dhillon; H Yan; S Farmer; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Introduction to the CANWARD study (2007–11).

Authors:  Daryl J Hoban; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2013-05       Impact factor: 5.790

3.  Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.

Authors:  Joseph Meletiadis; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 4.  Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance.

Authors:  Michel Pieren; Marcel Tigges
Journal:  Curr Opin Pharmacol       Date:  2012-07-25       Impact factor: 5.547

5.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

6.  Antimicrobial resistance is now widespread, warns WHO.

Authors:  Anne Gulland
Journal:  BMJ       Date:  2014-05-01

Review 7.  Mechanisms of resistance to quinolones.

Authors:  George A Jacoby
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

8.  Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.

Authors:  George G Zhanel; Mel DeCorby; Nancy Laing; Barb Weshnoweski; Ravi Vashisht; Franil Tailor; Kim A Nichol; Aleksandra Wierzbowski; Patricia J Baudry; James A Karlowsky; Philippe Lagacé-Wiens; Andrew Walkty; Melissa McCracken; Michael R Mulvey; Jack Johnson; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

Review 9.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success.

Authors:  Liam S Redgrave; Sam B Sutton; Mark A Webber; Laura J V Piddock
Journal:  Trends Microbiol       Date:  2014-05-16       Impact factor: 17.079

Review 10.  Quinolones: action and resistance updated.

Authors:  Karl Drlica; Hiroshi Hiasa; Robert Kerns; Muhammad Malik; Arkady Mustaev; Xilin Zhao
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

View more
  3 in total

1.  A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against P. aeruginosa.

Authors:  Liam Berry; Marc Brizuela; Gregory Jackson; Frank Schweizer
Journal:  RSC Med Chem       Date:  2021-07-27

2.  Dioctanoyl Ultrashort Tetrabasic β-Peptides Sensitize Multidrug-Resistant Gram-Negative Bacteria to Novobiocin and Rifampicin.

Authors:  Danyel Ramirez; Liam Berry; Ronald Domalaon; Yanqi Li; Gilbert Arthur; Ayush Kumar; Frank Schweizer
Journal:  Front Microbiol       Date:  2021-12-23       Impact factor: 5.640

Review 3.  Synergy by Perturbing the Gram-Negative Outer Membrane: Opening the Door for Gram-Positive Specific Antibiotics.

Authors:  Charlotte M J Wesseling; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-08-10       Impact factor: 5.578

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.